Continuing Medical Education (CME) Credits

ACCME Accredited

Accreditation Statement

The American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality and scientific integrity of the CME activity.

Designation Statement
The American Society of Cataract and Refractive Surgery designates this educational activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians may claim credit for participation as follows:

Friday: Skills Transfer Labs (max 4 credits)

Saturday: Ophthalmologists Program and Skills Transfer Labs (max 7.5 credits)

Sunday: Ophthalmologists Program (max 3.5 credits)

Physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credit TM.

Attendees registered as exhibitors, spouses and guests are not eligible for CME credits.

Target Audience

Anterior segment specialists, comprehensive ophthalmologists, residents, and fellows


Educational Objectives

Upon completion of this program, participants should be able to:

Ophthalmologist Program:

  • Develop appropriate cataract surgery treatment plans for more challenging eyes (post-refractive, irregular astigmatism, dry eye disease)
  • Explore innovations in topical, lens-based and corneal solutions for presbyopia correction to include patient selection for pseudophakic presbyopia management
  • Implement strategies for the surgical correction of astigmatism
  • Determine IOL power calculations for routine and challenging cases
  • Implement strategies to manage glaucoma surgical cases
  • Compare and contrast new advances in dry eye disease
  • Discuss the newest updates in corneal refractive surgery, including SMILE, corneal inlays, and collagen crosslinking.

Skills Transfer Labs:

  • Compare and contrast various ophthalmic surgical techniques on porcine or artificial eye models for ocular conditions: to include anterior segment and refractive surgery
  • Develop skills to manage intraoperative complications as reproduced in the lab setting
  • Formulate new skill sets through the use of new technologies and advanced devices
  • Increase proficiency and experience in a variety of corneal surgical procedures and suturing techniques.


ASOA Practice Management Sessions:

  • Identify and discuss current trends in employee recruitment and retention
  • Recognize and implement tools such as personality analysis and intergenerational communication strategies to aid in staff training and recruitment
  • Understand the importance of career pathing and professional development for practice management staff
  • Recognize and apply benchmarking best practices to enhance practice efficiency and profitability
  • Identify strategies for developing a leadership mindset.


Claim CME/CE Credits

Attendees will receive a post event survey and CME credit claim on Monday, August 22, 2022 via email. Please contact Janell John, ASCRS CME Coordinator, at with any questions on credit claims.

Scientific Integrity and Relevant Financial Interest Disclosure

ASCRS is committed to ensuring that all continuing medical education (CME) information is based on the application of research findings and the implementation of evidence-based medicine. ASCRS seeks to promote balance, objectivity and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose all relevant financial interests. ASCRS has mechanisms in place to mitigate all conflicts of interest prior to an educational activity being delivered to learners.

All faculty members are required to disclose whether they, or their spouses, have any financial interest (or lack thereof) from the past 24 months with an ineligible company whose primary business is to produce, market, sell, resell or distribute ophthalmic products or services consumed by, or used on, patients. Faculty members are also required to disclose such information verbally and on their first slide. It is an ASCRS requirement that all presenters disclose on the first slide and verbally at the beginning of any presentation whether they have any relevant financial interests from the past 24 months. Presenters are expected to give a fair and balanced presentation.

Notice About Off-Label Use Presentations

The educational program may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products or techniques presented.



Financial Interest Index

As a provider accredited by the Accreditation council for Continuing Medical Education, ASCRS must ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided activities.

All individuals participating in an activity designated for CME credit must disclose any financial interest or relationship with an ineligible company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services used on or by patients that are discussed in an educational presentation or lack thereof. Financial interest can include such things as grants or research support, consultant, stockholder, member of speaker’s bureau, et. Relationships held by a spouse, or a partner must also be disclosed.

The intent of this disclosure is not to disqualify anyone from participating, but to provide the program committee with information so they can design and implement a balanced, independent, and scientific educational activity. The Financial Interest Index provides information to attendees, so they can make their own judgement regarding the interest or relationship and the materials presented. A complete listing of relations disclosed, and their corresponding codes are below.


Zaina Al-Mohtaseb, MD                            Alcon, C; Allergan, C; Bausch & Lomb, C; CorneaGen, C; Johnson & Johnson, R; Ocular Therapeutic, C; Zeiss, C

Patti Barkey, COE                                      No Relevant Financial Interests

Hayley Boling, MBA, COE                          No Relevant Financial Interests

Daniel Chang, MD                                       AcuFocus, R; Allergan, C, R, L; Carl Zeiss Meditec, C, R, L;  Johnson & Johnson, C, R, L

Albert Cheung, MD                                     No Relevant Financial Interests

David Crandall, MD                                     Ivantis, C

Debbie Davis, COE                                     No Relevant Financial Interests

Marjan Farid, MD                                         Allergan, C; Bausch + Lomb, C; Johnson and Johnson, C; KALA, C; Novartis, C; Orasis, C; Sun Pharmaceuticals, C; Tarsus, C; Zeiss, C

Linda Georgian, COE                                  No Relevant Financial Interests

Heather Gerlach, ABO, COA, COE           No Relevant Financial Interests

Kourtney Houser, MD                                Bausch + Lomb, C; Novartis, C

Philip Isham, COE, OCS                             No Relevant Financial Interests

Allison Jarstad, DO                                     CorneaGen, L; Glaukos, C

Carrie Jacobs, COE, OCS                          No Relevant Financial Interests

Andrew Johnson, MD                                Ivantis, C

Sumitra Khandelwal, MD                           Alcon, C; Bausch + Lomb, C; Dompe, C; Tarsus, C

Douglas Koch, MD                                    Alcon, C; Bausch + Lomb, C; Carl Zeiss Meditec, C; Ivantis, O; Johnson & Johnson, C

Jennifer Loh, MD                                       Alcon, S; Allergan, C, L; Arc Scan, S; Bausch + Lomb, C; Johnson and Johnson, C; LensAR, C; Zeiss, C

Priya Mathews, MD                                   No Relevant Financial Interests

Cathleen McCabe, MD                             Alcon, C, R, L; Allergan/Abbvie, C, R, L; Bausch + Lomb, C, L; Eyepoint Pharmaceuticals, C, L; Eyevance, C;  Imprimis, C; iStar Medical, C; Lensar, C, L; Novartis, C; Ocular Therapeutix, C, R, L; Omeros, C, L; Orasis, R; Quidel, C; Science Based Health, C; Sight Sciences, C, L; Surface Pharma, R; Zeiss, C, L

Jake McMillin, MD                                     No Relevant Financial Interests

Beeran Meghpara, MD                              No Relevant Financial Interests

Manjool Shah, MD                                    AbbVie, C; Glaukos, C; Ivantis, C; Katena, C; ONL Therapeutics, C

Matthew Schulman, MD                           No Relevant Financial Interests

Eric Rosenberg, DO                                 Alcon, C, S, R, L; BVI, C; Zeiss, C

Kamran Riaz, MD                                     Bausch + Lomb, L; CorneaGen, L

Ben Seals, MBA                                        No Relevant Financial Interests

Inder Paul Singh, MD                                Allergan, C, R; Glaukos, C, R; iStar Medical, R; Ivantis, C, R; New World Medical, C, R; Quantel/Ellex, C; Sight Sciences, C, R;

William Trattler, MD                                Alcon, C, S; Allergan, C, S;  Azura, C; Bausch + Lomb, C, S, L; CXLO, O; Glaukos, C; Johnson and Johnson, C, L; Lensar, C; Novrtis, C; Ocular Therapeutix, S; Oculus, L; Omeros, C; Orasis, S; Sun, S, L; Zeiss, C, S

Nandini Venkateswaran, MD                   Alcon, C; Corneagen, L; Johnson and Johnson, L

Maureen Waddle, MBA                           BSM Consulting, C

Mitch Weikert, MD                                 Alcon Surgical, Inc., C; Carl Zeiss Meditec, Inc., C

Zachary Zavodni, MD                             No Relevant Financial Interests

ASCRS Staff Carrie Braden, Kristine Coan and Maria Rvan have no financial interests.

All of the relevant financial relationships list for these individuals have been mitigated.